Summary
19.5M world population suffer from Drug-Resistant Epilepsy (DRE) with symptoms poorly controlled. 8M are not eligible for brain surgery. Vagus nerve stimulation is nowadays the best treatment option. But unfortunately, current solutions do not reply to the clinical need. They cannot adapt to each patient making the patient's therapeutic journey complicated and expensive.
We created NAO.VNS, the next-generation implantable vagus nerve neurostimulator. We replaced metal wires by optical fibres to convert optical energy to electrical impulses rendering the device compliant with MRI & brain scans essential for disease diagnosis or treatment. Through NAO.VNS, patients & physicians receive remote feedback on the direct effect & efficacy of the neural stimulation, to precisely & uniquely adapt therapy.
Through EIC funding, we will complete a clinical pilot trial & a pivotal study in the EU/US to initiate market approvals. We expect to generate €89M by 2028 selling in the EU/US.
We created NAO.VNS, the next-generation implantable vagus nerve neurostimulator. We replaced metal wires by optical fibres to convert optical energy to electrical impulses rendering the device compliant with MRI & brain scans essential for disease diagnosis or treatment. Through NAO.VNS, patients & physicians receive remote feedback on the direct effect & efficacy of the neural stimulation, to precisely & uniquely adapt therapy.
Through EIC funding, we will complete a clinical pilot trial & a pivotal study in the EU/US to initiate market approvals. We expect to generate €89M by 2028 selling in the EU/US.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/190198268 |
| Start date: | 01-03-2023 |
| End date: | 28-02-2025 |
| Total budget - Public funding: | 4 471 250,00 Euro - 2 499 000,00 Euro |
Cordis data
Original description
19.5M world population suffer from Drug-Resistant Epilepsy (DRE) with symptoms poorly controlled. 8M are not eligible for brain surgery. Vagus nerve stimulation is nowadays the best treatment option. But unfortunately, current solutions do not reply to the clinical need. They cannot adapt to each patient making the patient's therapeutic journey complicated and expensive.We created NAO.VNS, the next-generation implantable vagus nerve neurostimulator. We replaced metal wires by optical fibres to convert optical energy to electrical impulses rendering the device compliant with MRI & brain scans essential for disease diagnosis or treatment. Through NAO.VNS, patients & physicians receive remote feedback on the direct effect & efficacy of the neural stimulation, to precisely & uniquely adapt therapy.
Through EIC funding, we will complete a clinical pilot trial & a pivotal study in the EU/US to initiate market approvals. We expect to generate €89M by 2028 selling in the EU/US.
Status
SIGNEDCall topic
HORIZON-EIC-2022-ACCELERATOROPEN-01Update Date
31-07-2023
Images
No images available.
Geographical location(s)
